Gennex Laboratories FY26 Results: Profit Growth Overshadowed by Audit Qualification and Cash Flow Woes

Consolidated Net Profit: ₹20.98 crore (₹2,097.88 lakh)
Consolidated Revenue: ₹172.74 crore (₹17,274.09 lakh)

Reader Takeaway: Healthy growth in profit and revenue, but auditor concerns and negative cash flow pose risks.

What just happened

Gennex Laboratories Limited announced its audited financial results for the fiscal year ended March 2026. The company reported a consolidated revenue of ₹172.74 crore, an increase of 25.26% from the previous year's ₹137.90 crore. Consolidated net profit also saw a rise of 15.78%, reaching ₹20.98 crore compared to ₹18.12 crore in FY25.

However, the company's statutory auditors issued a 'Qualified Opinion' on both standalone and consolidated financial statements. The qualification stems from the management's inability to obtain confirmations or reconciliations for significant balances across current and non-current assets, non-current liabilities, and current liabilities. The auditors stated that the impact of these unverified balances is 'unascertained'.

Furthermore, the consolidated operating cash flow for FY26 turned significantly negative, with an outflow of ₹-63.65 crore, a stark contrast to the ₹-10.80 crore outflow in FY25.

Why this matters

The qualified audit opinion is a significant red flag for investors, indicating potential issues with the accuracy and completeness of the company's financial reporting. Unverified asset and liability balances can obscure the true financial health of the company. The negative operating cash flow also raises concerns about the company's ability to generate cash from its core business activities, despite reporting accounting profits.

The backstory

This marks a critical juncture for Gennex Laboratories. While the company has shown revenue and profit growth over the past year, the auditor's concerns highlight underlying operational and accounting challenges. The company has previously reported positive or less negative operating cash flows, making the current year's substantial outflow a notable deterioration.

What changes now

Investors will be looking for concrete steps from Gennex Laboratories to address the auditor's concerns. The company has stated it is evaluating vendor solutions for 'Transaction Traceability Software' to improve accounting systems. Progress on implementing this software and resolving the unverified balances will be key. The company's ability to improve its operating cash flow generation in the upcoming quarters will also be closely watched.

Risks to watch

The primary risks include the potential for undisclosed liabilities or overstated assets due to unverified balances, which could impact future financial performance and shareholder value. The continued negative operating cash flow poses a risk to the company's liquidity and its ability to fund operations without external financing.

Peer comparison

Information on specific peers' recent financial results and audit opinions is not provided in the filing. Generally, qualified opinions are viewed negatively by the market, while strong positive operating cash flow is a sign of financial health. Companies with consistently positive operating cash flows are often favored by investors.

Context metrics (time-bound)

• Consolidated Revenue (FY26): ₹172.74 crore (+25.26% YoY)
• Consolidated Net Profit (FY26): ₹20.98 crore (+15.78% YoY)
• Consolidated Operating Cash Flow (FY26): ₹-63.65 crore (vs ₹-10.80 crore in FY25)

What to track next

Investors should closely monitor Gennex Laboratories' subsequent financial filings for the removal of the audit qualification. Progress in implementing accounting software to reconcile balances and improvements in operating cash flow will be crucial indicators to watch.